Palatin Technologies (PTN) 0.72 $PTN
Palatin ups earnings 178% in FQ2
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:41AM CST
PTN: 0.72 (-0.02)
Palatin Tech beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:36AM CST
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on February 13, 2015
PR Newswire - Fri Feb 13, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2014.
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2015 Results Teleconference and Webcast to be held on February 13, 2015
PR Newswire - Mon Feb 09, 3:39PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2015 operating results on Friday, February 13, 2015 before the open of the U.S. financial markets.
PTN: 0.72 (-0.02)
Palatin Technologies To Present At The BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 3:01PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
PTN: 0.72 (-0.02)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
FURX: 104.77 (-1.41), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
PR Newswire - Mon Dec 29, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program. The Company has initiated its phase 3 reconnect study in the United States for the treatment of female sexual dysfunction (FSD).
PTN: 0.72 (-0.02)
Palatin Completes $20 Million Equity and $10 Million Debt Financings
PR Newswire - Wed Dec 24, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has closed on a private placement of 2,050,000 shares of its common stock and Series C warrants to purchase 24,949,325 shares of its common stock. Funds under the management of QVT Financial LP invested $10 million and another accredited investment fund also invested $10 million. The funds paid $0.75 for each share of common stock and $0.74 for each Series C warrant, resulting in gross proceeds to Palatin of $20 million, with net proceeds, after deducting estimated offering expenses, of approximately $18.6 million.
PTN: 0.72 (-0.02), HRZN: 14.22 (+0.16)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/znzbgg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Aastrom Biosciences - Johnson & Johnson - AstraZeneca - Athersys - GlaxoSmithKline - Gilead Sciences - Merck & Co - Bioheart - Neurocrine Biosciences - Acorda Therapeutics - Les Laboratoires Servier - Bayer - Celladon - IntelGenx - Mesoblast - Palatin Technologies - Cardio3 BioSciences - La Jolla Pharmaceutical - Mast Therapeutics - NeoStem - Cytomedix - Torrent Pharmaceuticals - Juventas Therapeutics - Protemix Corporation - AngioDesign - Cardioxyl Pharmaceuticals - Innopharmax - QUANTUM GENOMICS - ARCA biopharma For more information visit http://www.researchandmarkets.com/research/zn...tive_heart
JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), MSTX: 0.47 (+0.01), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), PTN: 0.72 (-0.02), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACOR: 36.14 (-0.51)
Palatin Technologies' (PTN) CEO Carl Spana on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 18, 4:30PM CST
PTN: 0.72 (-0.02)
Palatin Technologies (PTN) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 18, 9:55AM CST
PTN: 0.72 (-0.02)
Palatin Tech earnings up 118% in FQ1
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 7:01AM CST
PTN: 0.72 (-0.02)
Palatin Tech EPS in-line
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:33AM CST
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014
PR Newswire - Tue Nov 18, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2014.
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2015 Results
PR Newswire - Thu Nov 13, 3:30PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2015 operating results on Tuesday, November 18, 2014 before the open of the U.S. financial markets.
PTN: 0.72 (-0.02)
Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:53PM CDT
Becton, Dickinson and Company (BDX) is set to report fourth-quarter fiscal 2014 results on Nov 4.
BDX: 143.71 (+0.72), ALNY: 95.54 (+1.67), PTN: 0.72 (-0.02), HSIC: 143.18 (+0.72)
Palatin Technologies To Present At The 13th Annual BIO Investor Forum
PR Newswire - Wed Oct 08, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting today at the 13th Annual BIO Investor Forum at 11:00 a.m. Pacific Time. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum will take place October 7-8 at The Palace Hotel in San Francisco, CA.
PTN: 0.72 (-0.02)
IPOs and Transactions Week in Review: September 29 - October 3
PR Newswire - Mon Oct 06, 1:25PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
RCAP: 10.28 (+0.28), CPTA: 18.72 (-0.03), PTN: 0.72 (-0.02), LPCN: 5.91 (+0.40), XGTI: 0.43 (+0.01), ENRJ: 2.81 (+0.06), SINO: 1.50 (unch)
Female Hypoactive Sexual Desire Disorder Therapeutics Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Wed Sep 24, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpm6jv/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - ANI Pharmaceuticals, Inc. Drug Profiles - flibanserin - testosterone - alprostadil - bremelanotide - (sildenafil testosterone) - (bupropion hydrochloride trazodone hydrochloride) - (buspirone hydrochloride testosterone) For more information visit http://www.researchandmarkets.com/research/cp...hypoactive
ANIP: 62.69 (-0.43), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
Palatin ups earnings 178% in FQ2
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:41AM CST
PTN: 0.72 (-0.02)
Palatin Tech beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:36AM CST
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on February 13, 2015
PR Newswire - Fri Feb 13, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2014.
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2015 Results Teleconference and Webcast to be held on February 13, 2015
PR Newswire - Mon Feb 09, 3:39PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2015 operating results on Friday, February 13, 2015 before the open of the U.S. financial markets.
PTN: 0.72 (-0.02)
Palatin Technologies To Present At The BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 3:01PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
PTN: 0.72 (-0.02)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
FURX: 104.77 (-1.41), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
PR Newswire - Mon Dec 29, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program. The Company has initiated its phase 3 reconnect study in the United States for the treatment of female sexual dysfunction (FSD).
PTN: 0.72 (-0.02)
Palatin Completes $20 Million Equity and $10 Million Debt Financings
PR Newswire - Wed Dec 24, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has closed on a private placement of 2,050,000 shares of its common stock and Series C warrants to purchase 24,949,325 shares of its common stock. Funds under the management of QVT Financial LP invested $10 million and another accredited investment fund also invested $10 million. The funds paid $0.75 for each share of common stock and $0.74 for each Series C warrant, resulting in gross proceeds to Palatin of $20 million, with net proceeds, after deducting estimated offering expenses, of approximately $18.6 million.
PTN: 0.72 (-0.02), HRZN: 14.22 (+0.16)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/znzbgg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Aastrom Biosciences - Johnson & Johnson - AstraZeneca - Athersys - GlaxoSmithKline - Gilead Sciences - Merck & Co - Bioheart - Neurocrine Biosciences - Acorda Therapeutics - Les Laboratoires Servier - Bayer - Celladon - IntelGenx - Mesoblast - Palatin Technologies - Cardio3 BioSciences - La Jolla Pharmaceutical - Mast Therapeutics - NeoStem - Cytomedix - Torrent Pharmaceuticals - Juventas Therapeutics - Protemix Corporation - AngioDesign - Cardioxyl Pharmaceuticals - Innopharmax - QUANTUM GENOMICS - ARCA biopharma For more information visit http://www.researchandmarkets.com/research/zn...tive_heart
JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), MSTX: 0.47 (+0.01), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), PTN: 0.72 (-0.02), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACOR: 36.14 (-0.51)
Palatin Technologies' (PTN) CEO Carl Spana on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 18, 4:30PM CST
PTN: 0.72 (-0.02)
Palatin Technologies (PTN) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 18, 9:55AM CST
PTN: 0.72 (-0.02)
Palatin Tech earnings up 118% in FQ1
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 7:01AM CST
PTN: 0.72 (-0.02)
Palatin Tech EPS in-line
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:33AM CST
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014
PR Newswire - Tue Nov 18, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2014.
PTN: 0.72 (-0.02)
Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2015 Results
PR Newswire - Thu Nov 13, 3:30PM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2015 operating results on Tuesday, November 18, 2014 before the open of the U.S. financial markets.
PTN: 0.72 (-0.02)
Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:53PM CDT
Becton, Dickinson and Company (BDX) is set to report fourth-quarter fiscal 2014 results on Nov 4.
BDX: 143.71 (+0.72), ALNY: 95.54 (+1.67), PTN: 0.72 (-0.02), HSIC: 143.18 (+0.72)
Palatin Technologies To Present At The 13th Annual BIO Investor Forum
PR Newswire - Wed Oct 08, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting today at the 13th Annual BIO Investor Forum at 11:00 a.m. Pacific Time. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum will take place October 7-8 at The Palace Hotel in San Francisco, CA.
PTN: 0.72 (-0.02)
IPOs and Transactions Week in Review: September 29 - October 3
PR Newswire - Mon Oct 06, 1:25PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
RCAP: 10.28 (+0.28), CPTA: 18.72 (-0.03), PTN: 0.72 (-0.02), LPCN: 5.91 (+0.40), XGTI: 0.43 (+0.01), ENRJ: 2.81 (+0.06), SINO: 1.50 (unch)
Female Hypoactive Sexual Desire Disorder Therapeutics Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Wed Sep 24, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpm6jv/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - ANI Pharmaceuticals, Inc. Drug Profiles - flibanserin - testosterone - alprostadil - bremelanotide - (sildenafil testosterone) - (bupropion hydrochloride trazodone hydrochloride) - (buspirone hydrochloride testosterone) For more information visit http://www.researchandmarkets.com/research/cp...hypoactive
ANIP: 62.69 (-0.43), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
